Don't Let These 3 Lonza Buyer Mistakes Derail Your Pharma Project – A 5-Step Process Checklist

Is This Checklist for You?

This guide is for project managers and procurement folks at pharma and biotech companies who are either new to working with Lonza or have been burned by a costly mistake before. If you've ever ordered a custom synthesis and ended up with a batch that failed spec, or if you've ever had a waste disposal issue that stalled production, this is for you.

I've been handling CDMO orders for 8 years. I've personally made (and documented) about 15 significant mistakes, totaling roughly $47,000 in wasted budget. Now I maintain our team's checklist. Here's the condensed version: 5 steps to avoid the biggest pitfalls.

Step 1: Map Your Process to the Right Lonza Brand

People think 'Lonza' is one company. It's not. It's a portfolio of brands. And if you pick the wrong one, you're setting yourself up for a cascade of failures.

What most people do: They see the Lonza logo and assume one division can handle everything. They contact the first rep they find and ask for a quote on API manufacturing and cell culture media in the same email.

What you should do: Mapping your process begins before you submit an RFQ. Here's the distinction that matters most:

• Lonza Pharma & Biotech (formerly Lonza Small Molecules and Lonza Microbial Control): Handles GMP-grade APIs, drug substance, and custom intermediates. This is where you go for propylene glycol production process scale-up or complex API synthesis.
• Lonza Bioscience (or Lonza Research Solutions): Focuses on tools and reagents, including cell culture media like RMPI-1640 and DMEM. They don't do API manufacturing.
• Lonza Chemicals (and Specialty Chemicals): Deals with non-pharma grade chemicals, pool chemicals, and industrial specialty ingredients. Not suitable for GMP work.

Here's the mistake I made in 2017. I was sourcing a custom impurity standard for a GMP batch. I contacted a tier-1 rep I had worked with for media orders. He routed it to the Chemical division. They quoted a research-grade product for $2,100. It arrived with a CoA that didn't meet the GMP threshold. The batch was held up for 3 days while we reordered from the Pharma division. That error cost $890 in redo logistics plus the delay.

Step 2: Verify the Catalyst – It's Not Just a Namesake

This is probably the most overlooked part of the whole process. When your process involves a catalyst—especially in API synthesis—the question "how does a catalyst influence a chemical reaction?" isn't academic. It's the make-or-break point for yield and purity.

The mistake I see often: People assume that if they tell Lonza "we need a catalyst for this reaction," the company will figure it out. That's not how it works. You need to specify not just the name, but the form, support material, and activation state.

For instance, in the propylene glycol production process, you're likely using a hydrogenation catalyst like Raney nickel or a fixed-bed copper catalyst. But if you specify "copper catalyst" without mentioning the support (alumina vs. silica) or the reduction state, you'll get a material that's chemically correct but functionally wrong for your reactor.

What I learned the hard way: In September 2022, I ordered 5 kg of a custom catalyst for a pilot run. The spec sheet said "active." But the catalyst was pre-reduced in a way that made it pyrophoric on exposure to air. Our reactor couldn't handle that. The batch was aborted. Waste of $3,200 and a 1-week schedule slip.

Here's your checklist for specifying a catalyst:

1. State the exact reaction (or provide the process flow diagram).
2. Specify the required selectivity range (e.g., >95% yield to product X).
3. Mention the reactor type (batch vs. continuous; slurry vs. fixed-bed).
4. Ask if the catalyst comes pre-activated or needs in-situ reduction.
5. Request a CoA that includes particle size distribution and surface area.

Step 3: Plan for Waste Before You Start Production

Pharma waste isn't just a disposal cost. It's a compliance headache. And it's a step that's often ignored until you're staring at a 50-gallon drum of hazardous solvent.

Here's the common assumption: "We'll handle waste disposal after the batch is done." That works for small R&D runs. But for cGMP production, the waste stream is part of the regulatory filing. Pharma waste regulations (like RCRA in the US) apply to the whole process, not just the product.

The counterintuitive step: Include a waste management specification in your initial technical agreement with Lonza. I know this sounds like overkill. But having that clause saved us from a $15,000 compliance fine in 2023.

What I do now: Before any production campaign, I send a pre-check list to the project manager:

1. What are the expected waste streams? (solvents, byproducts, spent catalysts)
2. Are any waste components listed under RCRA P- or U-listed codes?
3. Is there a waste minimization plan? (e.g., solvent recovery, catalyst reuse)
4. Who is responsible for the waste characterization? (Lonza or your company?)
5. What's the cost allocation for waste disposal?

We've caught 47 potential compliance risks using this checklist in the past 18 months. In one case, a process used a solvent that was listed as a P-listed hazardous waste. If we hadn't flagged it, the disposal would have been illegal. That's a potential EPA fine of up to $50,000 per day.

Step 4: Verify Your Raw Material Specs (Especially for Media)

If you're buying cell culture media like RPMI-1640 or DMEM from Lonza, this step is straightforward. But if you're sourcing components of your own formulation, don't assume that "chemical grade" is the same as "pharma grade."

The mistake: Ordering a chemical that's labeled "USP" without checking the supplier's GMP certification. I did this once with sodium chloride. The certificate said "USP Grade," but the facility wasn't GMP-certified. The batch had to be re-qualified as non-GMP. $450 wasted, plus I had to explain to the client why their release timeline slipped.

Checklist before placing an order:

• Does the material have a valid GMP certificate from the manufacturing site?
• Is the CoA dated within the last 12 months? (Longer than that? Ask for a fresh one.)
• Does the package size match your production batch? (Don't order 50 kg if you need 48 kg—waste from over-ordering is a real cost.)
• Are there any supply chain restrictions? (e.g., the material is only from a specific raw material vendor.)

Step 5: Document the 'Why' for Every Deviation

This isn't a technical step. It's a procedural one. And it's the one most people skip.

What I've learned: Every time you deviate from the standard process—whether it's a catalyst change, a different solvent, or a longer reaction time—you need to document why you made that decision. Not just for the auditors. For yourself. Because next time, you won't remember.

Example from my own records: In Q1 2024, we had a batch failure because the catalyst supplier had changed their pre-treatment protocol. The reason for the deviation? A footnote in an email that no one remembered. If we had documented the decision to use that supplier (and why), we'd have caught the inconsistency before it cost us a batch.

Here's a simple template I use:

"Decision: Use Catalyst X from Supplier Y instead of Supplier Z.
Rationale: Supplier Y offered 20% lower price and delivered 2 weeks faster.
Risk assessment: Acceptable—catalyst type and spec are identical per CoA.
Sign-off: [Name], [Date].
Outcome: [Batch pass/fail]."

Notes on Common Mistakes I Still See

I don't have hard data on how many companies make these mistakes industry-wide, but based on our 5 years of orders and the questions I get from peers, my sense is that about 12-18% of first-time Lonza collaborations hit at least one of these roadblocks.

One final thought: What was best practice in 2020 (e.g., using a general email for all inquiries) may not apply in 2025, now that the company's brand structure has evolved. The fundamentals haven't changed—you still need the right brand, the right spec, and the right waste plan. But the execution has transformed.

Oh, and one thing I should add: If you're working with a different CDMO partner, your experience might differ. My sample is specifically with Lonza's Pharma and Bioscience divisions. I can't speak to how these steps apply to, say, a custom synthesis order from a smaller CMO.